EMAP’s main objective is to carry out research related to the use of drugs in primary care, assessing their effectiveness, efficiency and safety. We are an interdisciplinary group with experience in conducting studies using different methodologies, mainly observational studies with Real World Data and pragmatic clinical trials with medicines and medical devices. These different approaches allow for studying drugs in conditions of usual care and real life, as well as focusing on vulnerable populations such as children, pregnancy and lactation, older people, polymedicated patients,? EMAP participates in conducting independent clinical trials through SCReN platform, national infrastructure for the development of independent research, is part of SIGMA Consortium, responsible for providing scientific evidence in pharmacoepidemiology through European databases, it is especially involved in the study of drug use during pregnancy (ConcePTION) and in pharmacovigilance of COVID-19 vaccines (VAC4EU) and participates in the Pharmacotherapeutic Harmonization program of CatSalut through the Pharmacoepidemiology Technical Office, studying the use of drugs in real conditions.
